Paula Casajust

7PUBLICATIONS
93CO-AUTHORS
Gastroenterology and hepatologySocial epidemiologyRecommender systemsPredictive and prognostic markersData quality
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Aug 09, 2025
Real-world management and outcomes of patients with hepatocellular carcinoma treated with systemic therapy in Spain: a patient cohort from the RETUD gastrointestinal registry.

Carlos López-López, Eva Martínez de Castro, Ana Fernández Montes

|Oct 21, 2024
Empagliflozin Use Is Associated With Lower Risk of All-Cause Mortality, Hospitalization for Heart Failure, and End-Stage Renal Disease Compared to DPP-4i in Nordic Type 2 Diabetes Patients: Results From the EMPRISE (Empagliflozin Comparative Effectiveness and Safety) Study.

Gisle Langslet, Thomas Nyström, Dorte Vistisen

|Sep 13, 2022
Empagliflozin reduces cardiorenal events, healthcare resource use and mortality in Sweden compared to dipeptidyl peptidase-4 inhibitors: Real world evidence from the Nordic EMPRISE study.

Thomas Nyström, Emilie Toresson Grip, Joel Gunnarsson

|Mar 29, 2022
Unraveling COVID-19: A Large-Scale Characterization of 4.5 Million COVID-19 Cases Using CHARYBDIS.

Kristin Kostka, Talita Duarte-Salles, Albert Prats-Uribe

|Jul 17, 2021
Characteristics and Outcomes of Over 300,000 Patients with COVID-19 and History of Cancer in the United States and Spain.

Elena Roel, Andrea Pistillo, Martina Recalde

|Mar 10, 2021
Unraveling COVID-19: a large-scale characterization of 4.5 million COVID-19 cases using CHARYBDIS.

Daniel Prieto-Alhambra, Kristin Kostka, Talita Duarte-Salles

Pageof 2

Frequent Collaborators

4 joint publications

Fredrik Nyberg

4 joint publications

Kristin Kostka

3 joint publications

Waheed-Ul-Rahman Ahmed

3 joint publications

Daniel Prieto-Alhambra